Navigation Links
Reportlinker Adds Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion
Date:1/11/2011

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

http://www.reportlinker.com/p0360249/Forecast-Insight-Antihypertensives---Fixed-dose-combinations-fail-to-offset-generic-erosion.html

IntroductionAs branded angiotensin receptor blockers (ARBs) lose market exclusivity, fixed-dose combinations become the only remaining products able to generate growth in the antihypertensives market. However, they will not be able to do enough to prevent market erosion which will fall from $37.5 billion in 2009 to $28.6 billion in 2019 at -3% CAGR.

Features and benefits

* Analysis of revenue and volume sales of antihypertensive drug classes in the seven major markets* Assess the impact of key patent expiries, such as Merck & Co's Cozaar and Hyzaar* Forecast antihypertensive revenue and volume sales to 2019, including performance of developmental agents* Understand the impact of clinical trials and pipeline agents on future market dynamics

HighlightsThe first triple drug combination; Exforge HCT (valsartan + amlodipine + hydrochlorothiazide) has reached the US market. Valturna (aliskiren + valsartan; Novartis) has combined the direct renin inhibitor aliskiren with the ARB valsartan to become the first drug to offer dual blockade of the renin angiotensin system.The only innovative antihypertensive agent expected to launch by 2019 is Takeda's ARB; azilsartan medoxomil (TAK-491). Launching in this time frame will make azilsartan an extremely late entry to the ARB class and the drug is going to experience of number of resistors to success.Japan has seen a number of recent launches of ARB combinations. If the new launches replicate the success of Hyzaar (launched in 2006) and Japanese physicians accept the ARB + CCB (calcium channel blocker) combination this will represent the strongest opportunity for class growth in the seven major markets.

Your key questions answered* Quantify and qualify antihypertensive sales in each of the seven major markets for 2006–2019* Examine the future performance of leading antihypertensive brands and how the growth of generics will impact revenues* Understand challenges faced by pipeline agents and new fixed-dose-combinations

To order this report:: Forecast Insight: Antihypertensives - Fixed-dose combinations fail to offset generic erosion

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Women's ... , Roberta Jordan is a Certified Nurse Midwife who was born and raised ... then went on to complete her masters degree from the University of Mexico. ...
(Date:5/24/2016)... ... 24, 2016 , ... Educational opportunities, and therefore life chances, ... communities providing richer opportunities. Recognizing the key role of housing in this system, ... school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused ...
(Date:5/24/2016)... ... 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research and ... protocols and patient results as have been achieved with Okyanos Cell Therapy ... of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
Breaking Medicine News(10 mins):